Evidence map›Paper›PMID 41541626›Full record

ArticleJournal of nutritional science2026

An open-label interventional study on efficacy and safety of 25 µg of daily calcifediol capsule versus 100 µg of cholecalciferol sachets in apparently healthy volunteers.

Ravi Shah, Liza Das, Dipika Bansal, Naresh Sachdeva, Michael F Holick, Pinaki Dutta, Sanja Medenica, Raman Kumar Marwaha

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nutritional science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ravi ShahDepartment of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.ORCID https://orcid.org/0009-0009-6893-2211
Liza DasDepartment of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.ORCID https://orcid.org/0000-0002-9701-9554
Dipika BansalDepartment of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India.
Naresh SachdevaDepartment of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Michael F HolickDepartment of Medicine, Section of Endocrinology, Diabetes, Nutrition and Weight Management, Boston University School of Medicine, Boston, MA, USA.
Pinaki DuttaDepartment of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.ORCID https://orcid.org/0000-0001-5415-1611
Sanja MedenicaDepartment of Endocrinology, Internal Medicine Clinic, Clinical center of Montenegro, University of Montenegro, Podgorica, Montenegro.
Raman Kumar MarwahaConsultant Endocrinologist and Scientific Advisor, International Life Sciences Institute (ILSI, India) and President Society for Endocrine Health Care of Elderly, Adolescents and Children (SEHEAC), New Delhi, India.ORCID https://orcid.org/0000-0001-7003-8766

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the multiple advantages of 25-hydroxyvitamin D (calcifediol or 25(OH)D) compared to cholecalciferol, it is used sparingly. This study was planned to assess the safety and efficacy of supplementing daily 25 µg of calcifediol capsules vis-a-vis 100 µg (4000 IU) of cholecalciferol sachets in apparently healthy individuals with vitamin D deficiency in Chandigarh, India (latitude 30.7° North, 76.8° East). It was a prospective, interventional study to evaluate the effects of calcifediol vis-a-vis cholecalciferol. Following initial screening of 70 subjects in each group, 62 were included in the calcifediol and 41 in the cholecalciferol group. Forty-six from calcifediol and 37 from cholecalciferol group completed the 6-month follow up. There was a significant increase in serum 25(OH)D (355% in cholecalciferol & 574% in calcifediol groups, respectively,

Indexed as

CalcifediolCholecalciferolDietary SupplementsVitamin D DeficiencyAdultCalciumCapsulesFemaleHumansIndiaMaleMiddle AgedParathyroid HormoneProspective StudiesVitamin DYoung Adult25-hydroxyvitamin DCalcifediolCalciumCapsulesCholecalciferolParathyroid HormoneVitamin D25(OH) D, 25 hydroxy vit. D25(OH)D3CalcifediolCholecalciferolECLIA, Electrochemiluminescence ImmunoassayiPTH, intact parathyroid hormoneVitamin D deficiencyβCTX Beta-Cross Laps, (C-terminal telopeptide of type 1 collagen)

Identifiers

PMID41541626
PMCPMC12800533

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.